Kesdoğan AB

Universitätsklinikum Aachen

1
Publications in this database

PubMed name variants: Kesdoğan AB. Uses the same surname-and-first-initial grouping as the researcher table; matches are not verified identities.

3
Career-wide h-index · OpenAlex
(21 citations, 6 total works)

Career-wide Research Topics · OpenAlex

Topic counts cover the OpenAlex author’s full publication record, across all conditions.

Ion channel regulation and function (6)Pain Mechanisms and Treatments (4)Ion Channels and Receptors (4)Botulinum Toxin and Related Neurological Disorders (2)Cardiac electrophysiology and arrhythmias (1)

Erythromelalgia Publications

Analgesic effect of Botulinum toxin in neuropathic pain is sodium channel independent.

Kesdoğan AB, Neureiter A, Gaebler AJ, Kalia AK, Körner J, et al.
Neuropharmacology •

Botulinum neurotoxin type A BoNT/A is used off-label as a third line therapy for neuropathic pain. However, the mechanism of action remains unclear. In recent years, the role of voltage-gated sodium channels (Nav) in neuropathic pain became evident and it was suggested that block of sodium channels by BoNT/A would contribute to its analgesic effect. We assessed sodium channel function in the presence of BoNT/A in heterologously expressed Nav1.7, Nav1.3, and the neuronal cell line ND7/23 by high throughput automated and manual patch-clamp. We used both the full protein and the isolated catalytic light chain LC/A for acute or long-term extracellular or intracellular exposure. To assess the toxin's effect in a human cellular system, we differentiated induced pluripotent stem cells (iPSC) into sensory neurons from a healthy control and a patient suffering from a hereditary neuropathic pain syndrome (inherited erythromelalgia) carrying the Nav1.7/p.Q875E-mutation and carried out multielectrode-array measurements. Both BoNT/A and the isolated catalytic light chain LC/A showed limited effects in heterologous expression systems and the neuronal cell line ND7/23. Spontaneous activity in iPSC derived sensory neurons remained unaltered upon BoNT/A exposure both in neurons from the healthy control and the mutation carrying patient. BoNT/A may not specifically be beneficial in pain syndromes linked to sodium channel variants. The favorable effects of BoNT/A in neuropathic pain are likely based on mechanisms other than sodium channel blockage and new approaches to understand BoNT/A's therapeutic effects are necessary.